Fundraising Fox

Avitide

Acquired

Lebanon, US · Founded 2012 · Delaware corporation · 3 known investors

avitide.com ↗
Advanced ManufacturingBiotechHardware

Founders & leadership

Avitide was founded in 2012 by Tillman Gerngross.

TG
Tillman GerngrossFounder
WK
Warren KettExecutive
JS
Jon ShellerExecutive
KI
Kevin IsettNamed on SEC filing
JS
Jonathan ShellerNamed on SEC filing
EA
Errik AndersonNamed on SEC filing
KI
Kevin IssettNamed on SEC filing

Board

CN
Claudio NessiBoard director
MRMichael Ross
Michael RossinBoard directorSenior Partner at SV Health Investors
RG
Rishi GuptainBoard directorPartner at OrbiMed
PF
Philip FerneauBoard director

Investors · 3

OrbiMedNew York · $1M – $75M
SV Health InvestorsBoston · $1M – $20M
Mithril Capital ManagementreportedAustinvia Ajay Royan · board

Reported raises · per SEC filings

Form D private placements

$39.5M disclosed across 6 rounds · 2014–2019

▶$10MraisedOct 2019 · 9 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Rishi GuptaDirector
  • Ajay RoyanDirector
  • Philip FerneauDirector
  • Claudio NessiDirector
  • Ian RatcliffeDirector
  • Tillman GerngrossDirector
  • Scott KennedyExecutive Officer
  • Kevin IsettExecutive Officer, Director
Offering amount
$10M
Amount sold
$10M
First sale
Oct 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$6.2MraisedAug 2018 · 4 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Tillman GerngrossDirector
  • Scott KennedyExecutive Officer
  • Rishi GuptaDirector
  • Ajay RoyanDirector
  • Philip FerneauDirector
  • Claudio NessiDirector
  • Ian RatcliffeDirector
  • Kevin IsettExecutive Officer, Director
Offering amount
$6.2M
Amount sold
$6.2M
Proceeds to insiders
$672K
First sale
Aug 2018
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$4MraisedJan 2018 · 3 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Warren KettExecutive Officer
  • Tillman GerngrossDirector
  • Claudio NessiDirector
  • Rishi GuptaDirector
  • Scott KennedyExecutive Officer
  • Ian RatcliffeDirector
  • Colin GreensponDirector
  • Philip FerneauDirector
  • Kevin IsettExecutive Officer, Director
Offering amount
$4M
Amount sold
$4M
Proceeds to insiders
$440K
First sale
Dec 2017
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$12MraisedJun 2017 · 10 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Ian RatcliffeDirector
  • Philip FerneauDirector
  • Rishi GuptaDirector
  • Colin GreensponDirector
  • Scott KennedyExecutive Officer
  • Michael RossDirector
  • Warren KettExecutive Officer
  • Tillman GerngrossDirector
  • Kevin IsettExecutive Officer, Director
  • Claudio NessiDirector
Offering amount
$12M
Amount sold
$12M
Proceeds to insiders
$682.5K
First sale
Jun 2017
Incorporated
Corporation, Delaware, 2012
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3.8MraisedAug 2015 · 11 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Kevin IsettExecutive Officer, Director
  • Claudio NessiDirector
  • Warren KettExecutive Officer
  • Jon ShellerExecutive Officer
  • Michael RossDirector
  • Rishi GuptaDirector
  • Philip FerneauDirector
  • Tillman GerngrossDirector
Offering amount
$7.7M
Amount sold
$3.8M
First sale
Jul 2015
Incorporated
Corporation, Delaware, 2012
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3.4MraisedJun 2014 · 7 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Jonathan ShellerExecutive Officer
  • Rishi GuptaDirector
  • Michael RossDirector
  • Errik AndersonDirector
  • Philip FerneauDirector
  • Warren KettExecutive Officer
  • Kevin IssettExecutive Officer, Director
Offering amount
$3.4M
Amount sold
$3.4M
First sale
May 2014
Incorporated
Corporation, Delaware, 2012
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 3

by search overlap
IDBiologics3 shared keywords
Qu Biologics3 shared keywordsQu Biologics develops treatments aimed at cancer, chronic inflammatory diseases, and metabolic diseases by restoring normal immune function. It operates in the biotech and immunotherapy space.
Leinco3 shared keywordsLeinco Technologies manufactures antibodies and proteins, offering both large- and small-scale IVD antibody and protein production along with CDMO services for scientists in life sciences discovery, biopharmaceutical, and diagnostics segments. Its reagents support research in areas such as cancer, infectious diseases, and immunology.

Companies competing with Avitide for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Biotech startup sells for $150 million - Valley Newsvnews.com · Sep 2021Avitide, Raises Series E Financing From Sands Capital Ventures With Broad Participation From Early Investors - BioSpacebiospace.com · Jun 2017Avitide Raises Funds For “On-Demand” Affinity Processinginsights.citeline.com · Sep 2015Biotech company Avitide pulls in Series C fundsventurecapitaljournal.com · Aug 2015Avitide nets $7.5M for its biologics manufacturing processmedcitynews.com · Aug 2015Avitide, Inc. Secures Series A Financing to Commercialize Novel Biopharmaceutical Affinity Purification Technology | Fierce Biotechfiercebiotech.com · Mar 2013

Frequently asked questions

Who founded Avitide?
Avitide was founded by Tillman Gerngross in 2012.
Who are Avitide's investors?
Avitide's investors include OrbiMed, SV Health Investors, Mithril Capital Management.
How much funding has Avitide raised?
Avitide has disclosed $39.5M raised across 6 rounds.
Where is Avitide headquartered?
Avitide is headquartered in Lebanon, US.